Pirtobrutinib results in reversible platelet dysfunction compared to ibrutinib and acalabrutinib
Alexander P. Bye, Neline Kriek, Tanya Sage, Suzannah J. Rawlings, Catherine Prodger, Murali Kesavan, Charlotte Lees, Stephen Booth, Louise G. Cowen, Kirsty Shefferd, Michael Desborough, Jonathan M. Gibbins, Toby A. Eyre
Abstract
Not available.
Topics & Concepts
IbrutinibPlateletMedicinePharmacologyInternal medicineLeukemiaChronic lymphocytic leukemiaChronic Lymphocytic Leukemia ResearchImmunodeficiency and Autoimmune DisordersLymphoma Diagnosis and Treatment